Direct Detection of Bloodstream Pathogens from Whole Blood using the LiDia-SEQ™ Platform: The First, NGS-Based Sample-to-Result Platform

Blood stream infections (BSI) or Sepsis is a life-threatening condition that affects more than 48 million people worldwide and contributes to approximately 11 million deaths per year. Current standard of care methods like blood culture can take days for results to be available. Sequencing to detect and identify a bloodstream pathogen is a manual process, with highly variable times to result. DNAe has developed a sample-to-result, NGS-based, BSI/AMR Test on our prototype LiDia-SEQ™ platform, that detects bacterial targets, with select antimicrobial resistance markers (AMR), and fungal targets directly from whole blood. The LiDia-SEQ™ platform consists of the system, test kits, and software.